688553 汇宇制药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入851,84429.24%927,0751,493,2681,823,7331,364,197
减:营业总成本741,46816.49%873,7121,304,3121,382,450985,736
    其中:营业成本143,51550.99%130,447176,182157,299116,243
               财务费用(13,695)-56.36%(41,802)(46,899)(4,955)3,184
               资产减值损失(9,605)281.57%(2,307)(3,933)(2,892)(4,671)
公允价值变动收益115,503--6,4402,3276,156--
投资收益15,370-25.42%34,18342,89412,84513,125
    其中:对联营企业和合营企业的投资收益648181.83%3071,4711,016--
营业利润244,418285.76%124,368235,448478,755398,002
利润总额250,053241.61%132,154238,391477,700396,457
减:所得税费用29,287-288.38%(7,180)(10,599)31,84154,633
净利润220,766148.76%139,335248,991445,859341,823
减:非控股权益(6,587)3,280.86%(451)----(1,501)
股东净利润227,352155.62%139,786248,991445,859343,324

市场价值指针
每股收益 (元) *0.540157.14%0.3300.5901.2000.950
每股派息 (元) *----0.2130.2350.211--
每股净资产 (元) *9.1604.63%8.9018.7778.4002.090
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容